122 related articles for article (PubMed ID: 20528668)
1. Insight into psoriasis management: commercial perspectives for the U.S. psoriasis market.
Tran B; Feldman SR
J Dermatolog Treat; 2011 Feb; 22(1):18-26. PubMed ID: 20528668
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
[TBL] [Abstract][Full Text] [Related]
3. What's new in the management of psoriasis?
Kinney MA; Feldman SR
G Ital Dermatol Venereol; 2009 Apr; 144(2):103-17. PubMed ID: 19357619
[TBL] [Abstract][Full Text] [Related]
4. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US.
Crown WH; Bresnahan BW; Orsini LS; Kennedy S; Leonardi C
Curr Med Res Opin; 2004 Dec; 20(12):1929-36. PubMed ID: 15701211
[TBL] [Abstract][Full Text] [Related]
5. Treatment and management of psoriasis with nail involvement: a focus on biologic therapy.
Langley RG; Daudén E
Dermatology; 2010; 221 Suppl 1():29-42. PubMed ID: 20733313
[TBL] [Abstract][Full Text] [Related]
6. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis.
Simpson JF; Yelverton CB; Balkrishnan R; Fleischer A; Lide W; Feldman SR
Manag Care Interface; 2006 Jun; 19(6):39-43. PubMed ID: 16892660
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis: issues far more serious than cosmetic.
Zanni GR
Consult Pharm; 2012 Feb; 27(2):86-8, 90, 93-6. PubMed ID: 22330949
[TBL] [Abstract][Full Text] [Related]
8. Do utilization management controls for phototherapy increase the prescription of biologics?
Simpson GL; Yelverton CB; Rittenberg S; Feldman SR
J Dermatolog Treat; 2006; 17(6):359-61. PubMed ID: 17853310
[TBL] [Abstract][Full Text] [Related]
9. A review of health outcomes in patients with psoriasis.
Li K; Armstrong AW
Dermatol Clin; 2012 Jan; 30(1):61-72, viii. PubMed ID: 22117868
[TBL] [Abstract][Full Text] [Related]
10. The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis - an introduction.
Freeman K
Curr Med Res Opin; 2011 Jan; 27(1):197-203. PubMed ID: 21142834
[TBL] [Abstract][Full Text] [Related]
11. The management of psoriasis in children and adolescents.
Pootrakul L; Kalb RE
G Ital Dermatol Venereol; 2010 Apr; 145(2):259-68. PubMed ID: 20467399
[TBL] [Abstract][Full Text] [Related]
12. Outcomes associated with the use of biologic agents in moderate to severe psoriasis.
Price J; Bhosle M; Feldman SR; Balkrishnan R
J Drugs Dermatol; 2007 Mar; 6(3):259-67. PubMed ID: 17373187
[TBL] [Abstract][Full Text] [Related]
13. Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis.
Yelverton CB; Kulkarni AS; Balkrishnan R; Feldman SR
Manag Care Interface; 2006 Jan; 19(1):33-6, 39. PubMed ID: 16453993
[TBL] [Abstract][Full Text] [Related]
14. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.
Krueger G; Koo J; Lebwohl M; Menter A; Stern RS; Rolstad T
Arch Dermatol; 2001 Mar; 137(3):280-4. PubMed ID: 11255325
[TBL] [Abstract][Full Text] [Related]
15. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Feldman SR; Evans C; Russell MW
J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
[TBL] [Abstract][Full Text] [Related]
16. Management and costs of severe psoriasis: the role of new biologics.
Feldman SR; Pearce DJ
Expert Rev Pharmacoecon Outcomes Res; 2004 Oct; 4(5):573-9. PubMed ID: 19807550
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies.
Pearce DJ; Nelson AA; Fleischer AB; Balkrishnan R; Feldman SR
J Dermatolog Treat; 2006; 17(1):29-37. PubMed ID: 16467021
[TBL] [Abstract][Full Text] [Related]
18. Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care?
Balkrishnan R; Bhosle MJ; Fleischer AB; Feldman SR
J Dermatolog Treat; 2010 May; 21(3):178-84. PubMed ID: 19821787
[TBL] [Abstract][Full Text] [Related]
19. Economic considerations in psoriasis management.
Radtke MA; Augustin M
Clin Dermatol; 2008; 26(5):424-31. PubMed ID: 18755360
[TBL] [Abstract][Full Text] [Related]
20. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting.
de Korte J; van der Valk PG; Sprangers MA; Damstra RJ; Kunkeler AC; Lijnen RL; Oranje AP; de Rie MA; de Waard-van der Spek FB; Hol CW; van de Kerkhof PC
Br J Dermatol; 2008 Feb; 158(2):375-81. PubMed ID: 18067483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
